


**Figure 1:** Representative examples showing the neuroprotective action of rotigotine measured on the basis of the density of the dopamine transporter as an indicator of the density of remaining nerve endings in the striatum




- Group 1: Untreated control group
- Group 2: Control group treated with vehicle solution for rotigotine and MPTP
- Group 3: MPTP treatment
- Group 4: MPTP treatment plus rotigotine 0.3 mg/kg
- Group 5: MPTP treatment plus rotigotine 1.0 mg/kg
- Group 6: MPTP treatment plus rotigotine 3.0 mg/kg
- Group 7: Treatment with rotigotine only (3.0 mg/kg)

2/2

**Figure 2:** Dopamine transporter (DAT) binding in the dorsal and ventral part of the striatum in different groups. Quantification of the DAT density as illustrated in Figure 1

\*: Significant drop in DAT binding compared to group 2

#: Significant preservation of DAT binding compared to group 3



Group 1: Untreated control group

Group 2: Control group treated with vehicle solution for rotigotine and MPTP

Group 3: MPTP treatment

Group 4: MPTP treatment plus rotigotine 0.3 mg/kg

Group 5: MPTP treatment plus rotigotine 1.0 mg/kg

Group 6: MPTP treatment plus rotigotine 3.0 mg/kg

Group 7: Treatment with rotigotine only (3.0 mg/kg)